Anti-Rheumatic Effect of Antisense Oligonucleotide Cytos-11 Targeting TNF-α Expression
The urgency of the search for inexpensive and effective drugs with localized action for the treatment of rheumatoid arthritis continues unabated. In this study, for the first time we investigated the Cytos-11 antisense oligonucleotide suppression of TNF-α gene expression in a rat model of rheumatoid arthritis induced by complete Freund's adjuvant. Cytos-11 has been shown to effectively reduce peripheral blood concentrations of TNF-α, reduce joint inflammation, and reduce pannus development. The results achieved following treatment with the antisense oligonucleotide Cytos-11 were similar to those of adalimumab (Humira®); they also compared favorably with those results, which provides evidence of the promise of drugs based on antisense technologies in the treatment of this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 22(2021), 3 vom: 20. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Makalish, Tatyana P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.04.2021 Date Revised 07.04.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms22031022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320603180 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320603180 | ||
| 003 | DE-627 | ||
| 005 | 20231225173932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms22031022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320603180 | ||
| 035 | |a (NLM)33498456 | ||
| 035 | |a (PII)1022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Makalish, Tatyana P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-Rheumatic Effect of Antisense Oligonucleotide Cytos-11 Targeting TNF-α Expression |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2021 | ||
| 500 | |a Date Revised 07.04.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The urgency of the search for inexpensive and effective drugs with localized action for the treatment of rheumatoid arthritis continues unabated. In this study, for the first time we investigated the Cytos-11 antisense oligonucleotide suppression of TNF-α gene expression in a rat model of rheumatoid arthritis induced by complete Freund's adjuvant. Cytos-11 has been shown to effectively reduce peripheral blood concentrations of TNF-α, reduce joint inflammation, and reduce pannus development. The results achieved following treatment with the antisense oligonucleotide Cytos-11 were similar to those of adalimumab (Humira®); they also compared favorably with those results, which provides evidence of the promise of drugs based on antisense technologies in the treatment of this disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Humira® | |
| 650 | 4 | |a TNF-α | |
| 650 | 4 | |a antisense technologies | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a phosphorothioate oligonucleotides | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Oligonucleotides, Antisense |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Golovkin, Ilya O |e verfasserin |4 aut | |
| 700 | 1 | |a Oberemok, Volodymyr V |e verfasserin |4 aut | |
| 700 | 1 | |a Laikova, Kateryna V |e verfasserin |4 aut | |
| 700 | 1 | |a Temirova, Zenure Z |e verfasserin |4 aut | |
| 700 | 1 | |a Serdyukova, Olesya A |e verfasserin |4 aut | |
| 700 | 1 | |a Novikov, Ilya A |e verfasserin |4 aut | |
| 700 | 1 | |a Rosovskyi, Roman A |e verfasserin |4 aut | |
| 700 | 1 | |a Gordienko, Andrey I |e verfasserin |4 aut | |
| 700 | 1 | |a Zyablitskaya, Evgeniya Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Gafarova, Elvina A |e verfasserin |4 aut | |
| 700 | 1 | |a Yurchenko, Kseniya A |e verfasserin |4 aut | |
| 700 | 1 | |a Fomochkina, Iryna I |e verfasserin |4 aut | |
| 700 | 1 | |a Kubyshkin, Anatoly V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 22(2021), 3 vom: 20. Jan. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:3 |g day:20 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms22031022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 3 |b 20 |c 01 | ||